Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

In previous trials, lanadelumab (Takhzyro, Takeda) reduced the frequency and ... with a mean number of attacks of 4.8 (standard deviation [SD], 8.2). In the pre-index period, 196 patients (99% ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

High Blood Pressure has become a major public health concern in recent times. Research into natural remedies for health ...

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

GSK had great expectations for Blenrep after its accelerated ... given the head-to-head comparison with the daratumumab-based standard of care regimen,” he added. Blenrep was the first BCMA ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. East Asian Americans are ...

Tokyo, Jan. 30 (Jiji Press)--Japan's Takeda Pharmaceutical Co. said Thursday that its president and CEO, Christophe Weber, will step down at its general shareholders meeting in June 2026.

Takeda Canada Inc. (Takeda ... who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...